Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2021 Jul 2

PMID 34209513

Citations 12

Authors

Julie Bolcaen

Shankari Nair

Cathryn H S Driver

Tebatso M G Boshomane

Thomas Ebenhan

Charlot Vandevoorde

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GB) remains the most fatal brain tumor characterized by a high infiltration rate and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is common in GB, which subsequently leads to the activation of many downstream pathways that have a critical impact on tumor progression and therapy resistance. Therefore, receptor tyrosine kinase inhibitors (RTKIs) have been investigated to improve the dismal prognosis of GB in an effort to evolve into a personalized targeted therapy strategy with a better treatment outcome. Numerous RTKIs have been approved in the clinic and several radiopharmaceuticals are part of (pre)clinical trials as a non-invasive method to identify patients who could benefit from RTKI. The latter opens up the scope for theranostic applications. In this review, the present status of RTKIs for the treatment, nuclear imaging and targeted radionuclide therapy of GB is presented. The focus will be on seven tyrosine kinase receptors, based on their central role in GB: EGFR, VEGFR, MET, PDGFR, FGFR, Eph receptor and IGF1R. Finally, by way of analyzing structural and physiological characteristics of the TKIs with promising clinical trial results, four small molecule RTKIs were selected based on their potential to become new therapeutic GB radiopharmaceuticals.

Citing Articles

Emerging and Biological Concepts in Pediatric High-Grade Gliomas.

Yoel A, Adjumain S, Liang Y, Daniel P, Firestein R, Tsui V Cells. 2024; 13(17.

PMID: 39273062 PMC: 11394548. DOI: 10.3390/cells13171492.

Glioblastoma Therapy: Past, Present and Future.

Obrador E, Moreno-Murciano P, Oriol-Caballo M, Lopez-Blanch R, Pineda B, Gutierrez-Arroyo J Int J Mol Sci. 2024; 25(5).

PMID: 38473776 PMC: 10931797. DOI: 10.3390/ijms25052529.

Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy.

Stachyra-Strawa P, Szatkowska-Sieczek L, Cisek P, Golebiowski P, Grzybowska-Szatkowska L Genes (Basel). 2024; 15(2).

PMID: 38397167 PMC: 10887630. DOI: 10.3390/genes15020177.

Comprehensive Molecular Genetic Analysis in Glioma Patients by Next Generation Sequencing.

Kim T, Lee A, Ahn S, Park J, Jeun S, Lee Y Brain Tumor Res Treat. 2024; 12(1):23-39.

PMID: 38317486 PMC: 10864139. DOI: 10.14791/btrt.2023.0036.

Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment.

Rahban M, Joushi S, Bashiri H, Saso L, Sheibani V Front Chem. 2024; 11:1325214.

PMID: 38264122 PMC: 10804459. DOI: 10.3389/fchem.2023.1325214.

References

Vaidyanathan G, Affleck D, Li J, Welsh P, Zalutsky M . A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB). Bioconjug Chem. 2001; 12(3):428-38. DOI: 10.1021/bc0001490. View

Hainsworth J, Ervin T, Friedman E, Priego V, Murphy P, Clark B . Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer. 2010; 116(15):3663-9. DOI: 10.1002/cncr.25275. View

Sepulveda-Sanchez J, Vaz M, Balana C, Gil-Gil M, Reynes G, Gallego O . Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro Oncol. 2017; 19(11):1522-1531. PMC: 5737732. DOI: 10.1093/neuonc/nox105. View

Cai W, Chen K, He L, Cao Q, Koong A, Chen X . Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007; 34(6):850-8. DOI: 10.1007/s00259-006-0361-6. View

Nayak T, Brechbiel M . Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem. 2009; 20(5):825-41. PMC: 3397469. DOI: 10.1021/bc800299f. View

Wehrenberg-Klee E, Redjal N, Leece A, Turker N, Heidari P, Shah K . PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance. Am J Nucl Med Mol Imaging. 2015; 5(4):379-89. PMC: 4529591. View

Yeh H, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez-Lepera C . Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A. 2011; 108(4):1603-8. PMC: 3029752. DOI: 10.1073/pnas.1010744108. View

van Dijk L, Yim C, Franssen G, Kaanders J, Rajander J, Solin O . PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts. Contrast Media Mol Imaging. 2015; 11(1):65-70. DOI: 10.1002/cmmi.1659. View

Nayak L, de Groot J, Wefel J, Cloughesy T, Lieberman F, Chang S . Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017; 132(1):181-188. PMC: 5588922. DOI: 10.1007/s11060-016-2357-9. View

10.

Xiao Q, Dong M, Cheng F, Mao F, Zong W, Wu K . [Corrigendum] LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling. Int J Oncol. 2019; 54(6):2257. PMC: 6521924. DOI: 10.3892/ijo.2019.4769. View

11.

Zustovich F, Landi L, Lombardi G, Porta C, Galli L, Fontana A . Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer Res. 2013; 33(8):3487-94. View

12.

Narayana A, Gruber D, Kunnakkat S, Golfinos J, Parker E, Raza S . A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg. 2011; 116(2):341-5. DOI: 10.3171/2011.9.JNS11656. View

13.

Cai W, Ebrahimnejad A, Chen K, Cao Q, Li Z, Tice D . Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging. 2007; 34(12):2024-36. DOI: 10.1007/s00259-007-0503-5. View

14.

Zhao X, Xie J, Chen X, Sim H, Zhang X, Liang Y . Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. Mol Pharmacol. 2012; 82(1):47-58. PMC: 3382829. DOI: 10.1124/mol.111.076299. View

15.

Yu A, Faiq N, Green S, Lai A, Green R, Hu J . Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. J Neurooncol. 2017; 134(2):357-362. PMC: 6135089. DOI: 10.1007/s11060-017-2533-6. View

16.

Nishina T, Takahashi S, Iwasawa R, Noguchi H, Aoki M, Doi T . Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors. Invest New Drugs. 2017; 36(3):424-434. DOI: 10.1007/s10637-017-0514-4. View

17.

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

18.

Schafer N, Gielen G, Kebir S, Wieland A, Till A, Mack F . Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. J Cancer Res Clin Oncol. 2016; 142(7):1581-9. DOI: 10.1007/s00432-016-2161-0. View

19.

Guessous F, Zhang Y, diPierro C, Marcinkiewicz L, Sarkaria J, Schiff D . An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem. 2009; 10(1):28-35. PMC: 3278215. DOI: 10.2174/1871520611009010028. View

20.

van den Bent M, Eoli M, Sepulveda J, Smits M, Walenkamp A, Frenel J . INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2019; 22(5):684-693. PMC: 7229258. DOI: 10.1093/neuonc/noz222. View